OncoPharm 7 + 3
5 snips
Mar 3, 2022 Delve into the fascinating origins of Acute Myelogenous Leukemia treatment with a look back at pivotal studies and key clinical trials. Discover the impactful evolution of the 7 plus 3 chemotherapy regimen that revolutionized AML therapy since the 1970s. The conversation also breezes through nostalgic references to 1975 films, weaving together a mix of historical insights and contemporary relevance in cancer treatment.
AI Snips
Chapters
Books
Transcript
Episode notes
Origin of 7 + 3 Regimen
- In 1973, Yeats first used a continuous seven-day infusion of cytarabine combined with three days of daunorubicin for AML treatment.
- Among eight patients treated, five out of five under 60 achieved complete remission, an impressive early result.
High-Intensity Chemo's Surprising Benefit
- Higher intensity 7 plus 3 chemotherapy reduced duration of aplasia and associated infections despite increased drug exposure.
- This surprising benefit improved remission induction morbidity and mortality in AML patients.
Age Affects AML Biology
- Older AML patients had fewer marrow leukemia cells compared to younger patients, reflecting different disease biology.
- This suggests older patients likely have AML evolving from prior hematologic conditions unlike younger patients with de novo AML.
